The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breastcancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early high-risk breastcancer. Already approved in ...
Results that may be inaccessible to you are currently showing.